Merck’s (NYSE:MRK) leading drug, Keytruda, has shown remarkable recent growth—a success story with a foreseeable conclusion. The pharmaceutical company’s strong performance has been largely driven by ...
Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is ...
Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...
The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
Major trial boost: Phase 2 data showed INBRX-106 plus Keytruda doubled response rates in high PD-L1 head and neck cancer patients. Deeper tumor shrinkage: Most responders in the combo arm had over 50% ...
Padcev plus Keytruda shows superior response and survival rates in first-line metastatic urothelial carcinoma treatment compared to chemotherapy. Padcev monotherapy provides clinical benefits in later ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results